Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inflectra Launch Prep Continues Post-Deadline, Pfizer Says

Executive Summary

The 180-day notification period has passed for biosimilar of Celltrion's Remicade, but Pfizer seems to be aiming for an at-risk launch sometime this year.

You may also be interested in...



Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira

Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.

FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi

Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.

Pfizer Eliminates Roadblock To Remicade Biosimilar Launch

October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel